The future of probiotics is here, and it's all about traceability and functionality. At the Growth Asia Summit 2026, Lucas Chang, R&D Manager at TCI, made a compelling case for a paradigm shift in probiotic delivery. Chang argues that the traditional approach, focused on logistics and survival, is no longer sufficient. Instead, we must address the biological challenges that probiotics face once they reach their destination. This means building an 'evidence chain' that traces the impact of probiotics on the microbiome, bioactive compounds, host response, and measurable outcomes. It's a game-changer, especially when it comes to healthy aging.
One of the most fascinating aspects of this shift is the recognition that biology doesn't decline at a constant pace. Instead, there are specific pressure points that emerge at different stages of life. Chang highlights a longitudinal study that revealed two major transitions. The first occurs around age 40, affecting lipid metabolism, alcohol metabolism, and cardiovascular health. The second transition happens around age 60, impacting immune regulation, carbohydrate metabolism, and oxidative stress. This means that two people of the same chronological age can have vastly different functional trajectories, with one person booking travel and the other doctor's appointments.
This raises a deeper question: how can we enhance our body's resilience to these biological challenges? Chang introduces the concept of 'resilience' as the space between two biological challenges, where the gut plays a pivotal role. By viewing the gut from this perspective, we can see that the gut-axis story extends far beyond digestion. It encompasses local microbial function, biological signals, distant phenotypes, and measurable impacts.
TCI has developed a patented probiotic strain, TCR711 (Bacillus coagulans TCI711), to target two common aging stresses: fat accumulation and alcohol consumption. In a randomized study, TCR711 improved liver-fat outcomes by 8.7% compared to a placebo, while also shifting the gut ecology. This suggests that the probiotic's impact on the liver is not isolated but part of a broader ecosystem. The study also revealed that TCR711 enhances alcohol clearance, with specific enzyme-related capabilities detected in the strain.
Chang emphasizes that engineering a functional probiotic is about more than just delivery; it's about the outcome. Instead of starting with a strain, we should begin with the desired health outcome and trace the biology backward. This approach allows us to define the microbial job and build the probiotic strain, function, and delivery around it. For instance, TCI has developed a liquid chocolate format that not only helps with survival but also builds consumers' daily habits. This format offers a low free-water, lipid-rich phase and reduced exposure to moisture and oxygen, making it a strain-compatible environment.
In my opinion, this shift in probiotic delivery is a significant development in the field of gut-axis science. It's a move from a narrow focus on survival to a broader understanding of the microbiome's role in health and aging. By embracing traceability and functionality, we can unlock new possibilities for enhancing our well-being and resilience. This is a fascinating and exciting time for probiotics, and I can't wait to see where the research takes us next.
